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The Differentiation and Protective 
Function of Cytolytic CD4 T Cells in 
influenza infection
Deborah M. Brown1,2* , Anna T. Lampe1,2 and Aspen M. Workman2†
1 School of Biological Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA, 2 Nebraska Center for Virology, University 
of Nebraska-Lincoln, Lincoln, NE, USA
CD4 T cells that recognize peptide antigen in the context of class II MHC can differ-
entiate into various subsets that are characterized by their helper functions. However, 
increasing evidence indicates that CD4 cells with direct cytolytic activity (CD4 CTL) play 
a role in chronic as well as acute infections, such as influenza A virus (IAV) infection. 
In the last couple of decades, techniques to measure the frequency and activity of 
these cytolytic cells has demonstrated their abundance in infections, such as human 
immunodeficiency virus, mouse pox, murine gamma herpes virus, cytomegalovirus, 
Epstein–Barr virus, and influenza among others. We now appreciate a greater role for 
CD4 CTL as direct effectors in viral infections and antitumor immunity through their 
ability to acquire perforin-mediated cytolytic activity and contribution to lysis of virally 
infected targets or tumors. As early as the 1980s, CD4 T cell clones with cytolytic 
potential were identified after influenza virus infection, yet much of this early work was 
dependent on in vitro culture and little was known about the physiological relevance of 
CD4 CTL. Here, we discuss the direct role CD4 CTL play in protection against lethal 
IAV infection and the factors that drive the generation of perforin-mediated lytic activity 
in CD4 cells in vivo during IAV infection. While focusing on CD4 CTL generated during 
IAV infection, we pull comparisons from the literature in other antiviral and antitumor 
systems. Further, we highlight what is currently known about CD4 CTL secondary and 
memory responses, as well as vaccination strategies to induce these potent killer cells 
that provide an extra layer of cell-mediated immune protection against heterosubtypic 
IAV infection.
Keywords: CD4 effectors, CD4 cytolytic cells, influenza A virus, perforin, granzyme B
CD4 CTL: HiSTORiCAL PeRSPeCTive
CD4 T cells differentiate into a number of different subsets based on the cytokine milieu and 
transcription factors expressed during activation and differentiation. These subsets are identified 
by canonical cytokine secretion patterns and their effector function. Traditional helper cell func-
tions during infection include TNF-α and IFN-γ secretion that activates other immune cells and 
Abbreviations: CD4 CTL, CD4 T cell with cytolytic potential; CTL, cytotoxic T lymphocyte; DLN, draining lymph node; 
GrB, granzyme B; IAV, influenza A virus; PR8, influenza A/Puerto Rico/8/34; Prf1, perforin; SLO, secondary lymphoid organs.
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can protect against intracellular infections (Th1), IL-4-induced 
class switching to IgE, and protection against extracellular 
worm infections (Th2), IL-17, and IL-22 secretion that promotes 
protection against extracellular bacterial and fungal infections 
(Th17), and IL-21 secretion that facilitates germinal center 
formation and class switching to protein antigens (Tfh) (1, 2). 
There has recently been an increase in the literature surround-
ing the differentiation, function, and memory potential of class 
II-restricted CD4 T cells with cytolytic properties (termed CD4 
CTL), yet identification of these cells dates back almost 40 years. 
Using Lyt-1+ (CD4) T cell clones, it was demonstrated that 
“helper” T cells could lyse allogeneic target cells similar to Lyt-
2+ (CD8) cells (3, 4). Although early work utilized allogeneic 
CD4 cell clones due to their high frequency in normal mice, in 
1985, CD4+ T cell clones were isolated after influenza A/Jap/57 
infection that were able to lyse influenza-infected target cells 
expressing class II, but not class I MHC, suggesting that CD4 
CTL activity developed after infection and subsequent in vitro 
culture (5). Further experiments determined that soluble 
mediators were not responsible for conferring cytotoxicity, sug-
gesting direct cell contact was required for lysis. Although these 
clones could also promote differing levels of helper activity in 
in vitro cultures, the magnitude of B cell antibody production 
was inversely correlated to cytotoxic activity (5). Although CD4 
CTL could be generated in vitro, the identification and subse-
quent in vivo relevance of these cells was not appreciated until 
years later.
In the last 10–15  years, accumulating evidence that CD4 
CTL are not an artifact of in vitro stimulation but rather develop 
via an alternative activation pathway separate from canonical 
T helper cells has gained acceptance. Most of this literature 
focused on the appearance or activation of CD4 CTL during 
chronic infection suggesting that repeated antigen exposure and 
terminal differentiation were hallmarks of the CD4 CTL pheno-
type (6, 7). CD4 CTL developed in response to cytomegalovirus 
(CMV) (7, 8), human immunodeficiency virus (HIV) (9, 10), 
and Epstein–Barr virus (EBV) (11, 12) infection in humans as 
well as lymphocytic choriomeningitis virus (LCMV) (13, 14) 
and mouse gammaherpes virus (15, 16) in mice. In most of these 
infections, CD4 CTL were important effector cells and, in some 
cases, responsible for vaccination-induced protection against 
infection (17, 18). However, CD4 CTL have also been identified 
in acute infections, such as LCMV clone 13 (13), mouse pox (17), 
and influenza A virus (IAV) infection in both humans (19) and 
mice (20–22).
Many of the early reports detailing the appearance of CD4 
CTL did not identify the mechanism of cell killing by clones 
generated in vitro although, by the 1990s, it was reported that the 
cell surface receptor:ligand pair, Fas:FasL, was a major mecha-
nism of cell death induced by CD4 CTL during interaction with 
virally infected B cells (23) or in infection with LCMV (14). More 
recent data have provided evidence that CD4 CTL can utilize the 
perforin–granzyme pathway of target cell killing to act as primary 
lytic effectors for many viral infections (24) including mouse 
gamma herpes virus (15), mouse pox (17), and IAV (19–21). In 
fact, during IAV infection in vivo, CD4 CTL exclusively use the 
perforin–granzyme B (GrB) pathway for cell killing.
IN VITRO AND IN VIVO GeNeRATeD CD4 
CTL AS DiReCT eFFeCTORS AGAiNST 
iNFLUeNZA iNFeCTiON
Building on early evidence that CD4 CTL clones could be gen-
erated by IAV infection (5), Graham and Braciale generated a 
panel of CD4 Th1 and Th2 helper cell clones after inactivated 
IAV and incomplete Freund’s adjuvant injection (25). It was 
shown that Th1 clones, but not Th2 clones, could lyse influenza 
infected targets and indicated that CD4 CTL could be generated 
after vaccination as well as live infection. Further, Th1 clones, 
but not Th2 clones, could protect mice against lethal influenza 
infection, although the mechanism of killing was not elucidated 
at that time (25). With the advent of TCR tg mice specific for 
influenza peptide from hemagglutinin (HA) 126–138 in the 
context of class II I-Ad, Brown et al. revisited the idea that only 
Th1 polarized cells acquired cytolytic activity and investigated 
the mechanisms of protection in a monoclonal population of 
CD4 effectors generated in vitro. It was demonstrated that CD4+ 
effectors generated under Th1 polarizing conditions, but not 
Th2 polarizing conditions, could protect mice against highly 
pathogenic H1N1 IAV infection after adoptive transfer (26). 
Interestingly, CD4 T cells needed to be activated prior to adop-
tive transfer, as high numbers of naïve CD4 cells could not afford 
protection against lethal Influenza A/Puerto Rico/8/34 (PR8) 
infection. It was shown that host T cells were not required for 
protection mediated by CD4 effectors; however, host B cell anti-
body production was induced by Th1 effectors and this effect was 
IFN-γ independent. Moreover, at high dose PR8 infection (10 
LD50), CD4 effectors and passive transfer of antibodies protected 
B cell-deficient mice from highly pathogenic H1N1 infection 
(26). Surprisingly, a more direct role for CD4 effectors was found 
when B cell-deficient mice were given Th1 effectors and survived 
a lethal dose of PR8 H1N1. Additionally, it was demonstrated 
that perforin-mediated cytotoxicity was the mechanism utilized 
by Th1 effectors responsible for protection as perforin-deficient 
CD4 cells could not abrogate weight loss or survival. These 
cytolytic CD4 effectors resembled the early anti-influenza Th1 
clones generated by Graham and Braciale, yet were developed 
in  vitro with peptide pulsed APC and cytokine polarization. 
Culture conditions for generating these potent anti-influenza 
effectors required low dose peptide pulsed antigen-presenting 
cells, as anti-CD3 and anti-CD28 or high concentrations of 
soluble peptide added directly to cultures of APC and T cells 
did not induce antigen-specific cytolytic CD4 cells (27). This 
further suggests that an APC-derived second signal is required 
to generate protective CD4 CTL.
Protection from lethal dose IAV infection mediated by Th1 
clones or effectors generated in vitro indicated that CD4 CTL could 
have direct effects on viral replication. However, these in  vitro 
generated effectors were quite homogeneous and displayed char-
acteristics that might not reflect physiological phenotypes. Thus, 
IAV-specific CD4 effectors were generated in  vivo by isolating 
CD4+ cells from the lung and draining lymph node (DLN) at the 
peak of the response after sublethal PR8 infection and adoptively 
transferred into naïve hosts that were then given lethal doses of 
PR8. These IAV-specific CD4+ cells protected mice from five LD50 
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dose of PR8 IAV infection, but unlike in vitro-generated effectors, 
protection mediated by in vivo-generated effectors was partially 
dependent on IFN-γ. Similar to in  vitro-generated effectors, 
primary in vivo-generated effectors developed perforin-mediated 
cytotoxicity that was partly responsible for protection in a model 
of lethal IAV infection (20).
Investigators have also shown direct effects of memory 
CD4 T cells in protection against influenza infection (28, 29). 
These studies used an adoptive transfer system in which naïve 
TCR tg CD4 cells specific for HA peptide were primed in vitro, 
subsequently transferred to normal mice, and allowed to transit 
to the memory phase. It was demonstrated by two independent 
groups that CD4 memory cells had direct effects on influenza 
virus clearance (28, 29). Further studies using CD4 memory 
cells deficient in IFN-γ, perforin (Prf1), or host mice deficient 
in different cell populations demonstrated that CD4 memory 
cells protected mice using multiple and synergizing mechanisms 
where host immune cells, IFN-γ, and perforin all played a role 
(28, 30). Viral replication was blunted by both WT and Prf1−/− 
effectors; however, a high percentage of viral escape mutants 
were isolated from mice given WT, but not Prf1−/− memory cells, 
suggesting that perforin expressing CD4 CTL drive selection of 
epitope-specific escape mutants during lethal influenza infection. 
Overall, the requirement for perforin expression by CD4 CTL in 
promoting protection against lethal IAV infection was dependent 
on effector cell activation and immune competency of recipient 
mice. Nonetheless, CD4 CTL can mediate viral clearance directly 
through cytotoxic mechanisms.
CD4 CTL iN THe PRiMARY ReSPONSe TO 
iNFLUeNZA
The overwhelming evidence that CD4 CTL provided protection 
against lethal IAV infection led us to investigate whether CD4 
CTL could be activated during the primary response to IAV. 
Brown et  al. tracked both the TCR tg CD4 response specific 
for influenza HA126–138 in an adoptive transfer model and the 
endogenous peptide specific response to characterize the CD4 
CTL response to primary infection (20). Using CD4 TCR tg cells, 
it was concluded that only cells in lung, but not DLN, expressed 
GrB and acquired perforin-mediated cytotoxicity by 7  days 
post-IAV infection. Moreover, the same result in the endogenous 
response to infection was observed, but this response peaked at 
days 9–10. Not surprisingly, the GrB and perforin levels and lytic 
capacity of CD4 CTL in our study did not reach the magnitude 
as that seen in CD8+ CTL (20). This is in contrast to the LCMV 
system, in which CD4 CTL were reported to be as robust as CD8 
CTL in lytic activity when adjusted for E:T ratios and functional 
avidities (31). Our findings were confirmed and extended by 
Hua et al., in which influenza-infected mice increased GrB and 
perforin expression by CD4 effectors in the lung, but not the 
DLN, 7 days post-infection. The TCR tg adoptive transfer model 
using Ova-specific CD4 cells (OT-II) and Ova-expressing PR8 
virus was used in this report. Moreover, antigen-specific CD4+ 
T cells (as measured by IFN-γ expression) in the lung could 
degranulate as determined by increased CD107a expression (21). 
Taken together, two independent groups have determined that 
CD4 CTL activity is apparent in CD4 effectors in the lung, which 
correlates to IFN-γ expression (21), but does not require INF-γ 
for differentiation or effector function (20).
Unlike CD8+ CTL, in which a small percentage of cells express 
GrB in the DLN and can lyse target cells, CD4 CTL in the DLN 
express little to no GrB protein by flow cytometric analysis. In 
contrast, Hua et  al. demonstrated that approximately 20% of 
the DLN CD4+ cells generated after IAV infection expressed 
perforin protein, yet our work suggests that CD4 CTL in sec-
ondary lymphoid organs (SLO) do not have the capacity to lyse 
peptide expressing targets, even when directly isolated via cell 
sorting techniques (20). While intracellular GrB expression can 
be detected directly ex vivo, perforin detection in both CD8 and 
CD4 cells by flow cytometry has proven more difficult (31–33). 
Polyclonal activation with PMA and ionomycin was necessary to 
detect perforin protein intracellularly in DLN CD4 cells by flow 
cytometry (21) yet direct ex vivo expression or expression after 
peptide restimulation has been difficult to detect (22, 31, 34). 
These issues need further investigation to elucidate the relation-
ship between GrB and perforin expression in influenza infection. 
Analysis of perforin expression by Western blot in in  vitro- 
generated CD8 (34) and CD4 (22) T cells has demonstrated 
that GrB and perforin are regulated differently with GrB usually 
expressed prior to and at higher levels than perforin. Moreover, 
not all GrB expressing cells can degranulate or mediate killing 
activity suggesting that GrB expression does not directly correlate 
to perforin expression (35). Recently, a new method has been 
described that utilizes fixatives commonly used in immunohisto-
chemistry to demonstrate perforin expression by flow cytometry 
in CD8 CTL after in vitro activation (32). GrB and perforin double 
staining has been shown by this technique and our lab is pursuing 
this method to further understand the expression patterns of GrB 
and perforin and how that relates to degranulation in CD4 CTL 
during influenza infection.
Although work presented thus far deals exclusively with CD4 
CTL in mouse models of IAV infection, there have been reports 
detailing the identification of CD4 CTL in humans after vaccina-
tion (36, 37) or experimental IAV infection (19). Wilkinson et al. 
demonstrated that influenza-specific CD4 cells expressing GrB 
and exhibiting CTL activity were present at baseline and 7 days 
post-IAV infection in healthy volunteers. Moreover, CD4-specific 
and perforin-dependent CTL activity correlated to lower disease 
metrics as measured by illness duration and symptom scores. In 
this study, volunteers were excluded on the basis of preexisting 
antibody responses to the experimental strains and CD8 T cell 
responses did not appear to correlate to disease scores (19). 
However, in a study done in populations naturally exposed to 
pandemic IAV, it was demonstrated that a higher frequency of 
cross reactive IFN-γ+ CD8+ T cells correlated to asymptomatic 
protection in the absence of neutralizing antibodies (38). In these 
correlation studies, the cooperative effects of CD4 and CD8 T 
cells cannot be adequately controlled for, yet both CD4 and CD8 
T cells are specific for the internal, conserved IAV proteins sug-
gesting that T cells may cooperate to diminish viral titers early 
in infection. In a mouse model of protection, McKinstry et  al. 
demonstrated that CD4 memory cells were more effective when 
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transferred to CD8-sufficient hosts compared to CD8-deficient 
hosts, suggesting that CD4 memory cells can cooperate with CD8 
cells in promoting protection (28). Taken together, CD4 CTL rep-
resent an important antiviral effector of cell-mediated immunity 
that has direct effects on viral titers and disease progression in 
humans (19) as well as mice (20, 26, 28).
FACTORS THAT DRive THe 
DiFFeReNTiATiON OF CD4 CTL
Various studies have begun to elucidate the factors that drive 
CD4 CTL differentiation during influenza infection in  vivo 
(20–22, 39). While it has become apparent that cytokines and 
transcription factors important in driving CD8 CTL function 
may have a role in CD4 CTL differentiation, these cell types 
remain fundamentally distinct. However, similar to CD8 CTL 
generation, a role for IL-2 in driving the cytolytic phenotype in 
CD4 T cells was identified (22, 27). In vitro, low dose (10 ng/ml) 
exogenous IL-2 promotes high levels of GrB and moderate 
levels of perforin as measured by Western blot (22). While these 
in vitro-generated CD4 CTL can lyse targets with high efficiency, 
the use of Prf1-knockout T cells indicated that the cytolytic activ-
ity that does occur is partially mediated by Fas/FasL and partially 
mediated by perforin (20, 27). The correlation of CTL activity 
and GrB expression in the Th1, but not Th2, subsets led to further 
investigation of the cytokine factors necessary for CD4 CTL 
generation in vitro. Although naïve cells incubated with peptide 
pulsed APC and IL-2 alone induced GrB and CTL activity, it was 
demonstrated that addition of IL-12 or IL-6 could induce higher 
levels of perforin expression by Western blot (40). Moreover, 
addition of the type I interferon (IFN), IFN-α to in vitro cultures 
results in slight increases in GrB production by CD4 T cells and 
IFN-α and IL-2 in combination have synergistic effects on GrB 
production, perforin expression, and CD4 CTL target killing (21). 
Interestingly, in vivo, IAV infection drives CTL activity mediated 
exclusively by perforin (19, 20), making an interpretation of the 
cytokine requirements for driving this cell type during natural 
infection relatively straightforward (21, 22, 39).
The role of IL-2 signaling in driving CD4 CTL activity in vivo 
was revealed by the use of high affinity IL-2 receptor (Il2rα)-
deficient mice (21, 22). IL-2Rα deficiency resulted in low GrB 
expression in the lung indicating a requirement for IL-2 signaling 
for CD4 CTL differentiation (21, 22). Interestingly, there was a 
dose dependent requirement for IL-2 receptor signaling as CD4 
T cells that have intermediate expression of IL-2Rα (IL-2Rα+/−) 
exhibit intermediate GrB production and target cell killing com-
pared to wild type CD4 T cells and IL-2Rα−/− CD4 T cells (22).
As discussed above, CD4 T cells expressing GrB and perforin 
can be found at the site of infection, the lung, but not the DLN 
or spleen, after IAV infection (20–22). This localized phenotype 
suggests that different conditions in these two environments 
affect the development of CD4 CTL, with the environment of the 
lung being better suited for CD4 CTL differentiation and activity. 
As the lung is the site of active viral replication, one difference 
between the lung environment and the DLN after IAV infection 
is the composition and amount of cytokines present. The lung 
expresses higher amounts of IFN-α than the DLN at day 5 post-
infection (21) as well as other proinflammatory cytokines, such as 
IL-6 and TNF-α (40). The necessity for Type I IFN in promoting 
the cytolytic phenotype was confirmed using IFNAR1-deficient 
mice that were infected with IAV. Compared to WT mice, 
IFNAR1-deficient mice showed lower levels of GrB and perforin, 
and this was further decreased in the presence of anti-IL-2 anti-
bodies, suggesting that type I IFN and IL-2 cooperate to drive 
CD4 CTL generation during IAV infection (21).
Cytokine signaling results in the activation of kinases and 
subsequent phosphorylation and dimerization of signal trans-
ducer and activator of transcription (STAT) proteins. Since it 
has been determined that IL-2 is required for CD4 CTL develop-
ment, the role played by Jak3 and STAT5 have been investigated. 
Pharmacological inhibitors of both Jak3 and STAT5 lead to 
decreased GrB expression and lower cytolytic activity (22). Taken 
together, these results suggest that extended signaling through 
Jak3 and STAT5 induced by IL-2 are necessary for optimal CD4 
CTL formation. In addition, Type I IFNs, such as IFN-α, signal 
through the signal transducer STAT2, which appears to play a role 
in GrB expression, as STAT2 deficiency results in decreased GrB 
expression by CD4 T cells in the lung after IAV infection (21). 
Investigating other intracellular signaling pathways involved in 
driving perforin-mediated CD4 CTL activity will provide further 
insight into the environmental signals required for CD4 CTL 
differentiation.
Whether the same antigen-presenting cell delivers these 
signals simultaneously and whether distinct signals are separated 
by space and time are questions that remain to be answered. It is 
interesting to postulate that migratory dendritic cells that deliver 
antigen to the DLN from the lung could provide initial signals for 
activation, such as IL-12, that induce autocrine IL-2 production 
by CD4 CTL precursors. Data from Brown et al. and Hua et al. 
support this notion as IL-2 production in the DLN is readily 
apparent (21), even in situations where inflammation in the lung 
is different (40). Once CD4 CTL precursors migrate to the lung, 
they receive additional signals, such as IFN-α (21) or IL-6, from 
alveolar Mφ or other APC in the parenchyma (20). After terminal 
differentiation into competent CTL, CD4 cells can migrate to the 
airways to interact with and lyse class II expressing epithelial cells 
(20), thus providing an extra layer of heterosubtypic protection, 
especially for highly pathogenic IAV strains.
It has been known for many years that transcription factors 
regulate the differentiation of distinct CD4 T helper cell subsets 
with T-bet being the master regulator of Th1 polarization and 
GATA-3 driving Th2 polarization [reviewed in Ref. (1, 2)]. 
However, whether CD4 CTL comprise a new type of T helper 
subset, with distinct transcription factor requirements, is a matter 
of intense investigation. In many cases, CD4 CTL differentiation 
follows a Th1 developmental pathway with IL-12 but not IL-4 
contributing to GrB and perforin induction (26, 27). CD8 CTL 
have been shown to require the coordinated expression of Runx3, 
T-bet, and Eomesodermin (Eomes) for full CTL activity and 
progression to memory [for review, see Ref. (33, 41)]. In mouse 
models to elicit antitumor immunity, immunotherapy using dual 
costimulatory agonist antibodies to CD134 (OX-40) and CD137 
(4-1BB) induces Eomes in CD4 CTL that is necessary for GrB 
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expression (42). Other groups have also demonstrated a role for 
Eomes in CD4 CTL differentiation after various immunotherapy 
regimens (43, 44); however, these therapies are designed to over-
come tolerance induction and may reflect high levels of activation 
in the CD4 T cell compartment, driving toward a more CD8-like 
phenotype. In contrast, during IAV infection, Eomes expression 
is low in CD4 CTL in the lung (20) and does not appear to be 
regulated by IL-2 signaling (22). Conversely, IAV-specific CD4 
CTL in the lung express more T-bet than cells in the DLN and 
spleen, and this expression is regulated by IL-2 and IFN-α in vivo 
(20–22). When T-bet is knocked out, CD4 T cells in the lung 
express less GrB and perforin, but addition of T-bet to CD4 T cells 
from SLO does not increase GrB expression, indicating that T-bet 
alone is not sufficient to induce CD4 CTL (21). The transcrip-
tion factor shown to regulate both T-bet and cytolytic proteins 
in CD4 T cells is Blimp-1, a transcriptional repressor. Blocking 
IFN-α signaling was shown to decrease Blimp-1 expression in 
CD4 CTL in the lungs of IAV-infected mice. Moreover, Blimp-1 
was required for CD4 cell expression of GrB and cytolytic activity 
and protection against IAV infection in vivo (21). Blimp-1 was 
also shown to promote T-bet binding to GrB and Prf1 promotor 
regions, thus regulating cytolytic activity at the molecular level. 
Comparisons between the tumor immunotherapy and infection 
models reveal that different stimuli can induce distinct transcrip-
tion factor expression in CD4 CTL with dual costimulation 
inducing Eomes and IAV infection inducing T-bet and Blimp-1. 
However, until the transcription factors involved in CD4 CTL 
development become more clearly defined, the debate whether 
CD4 CTL make up a distinct subset of the CD4 T cell lineage or 
are a terminally differentiated Th1 cell will remain unresolved.
ARe CD4 CTL PReSeNT iN THe MeMORY 
POOL?
It is clear that CD4 CTL arise during IAV infection and both 
cytokines and transcription factors are important in driving CD4 
CTL differentiation. However, questions still remain regarding 
the memory potential of these cells and whether they transition 
to CD4 memory cell populations resident in the lung or SLO. 
Studies in humans suggest that CD4 CTL are present in the 
memory pool, since these effectors are described as “preexist-
ing” in experimental IAV infection (19) and in vaccinated older 
adults (37). However, in IAV vaccination studies in humans (37) 
and in mouse models of vaccination (45) or secondary infection 
(46), the cells that are being assayed for are probably more aptly 
named secondary effectors. CD4 CTL, such as CD8 memory 
CTL, at the memory stage do not express cytolytic proteins until 
restimulated in  vitro (37, 45, 47) and without identification of 
cell surface markers, the transition from effector CD4 CTL to 
memory is difficult to monitor. Just recently, the class I-restricted 
T cell-associated molecule (CRTAM) known to be expressed on 
CD8 T cells and NK cells has been identified on a fraction of CD4 
T cells that develop cytotoxicity in vivo (39). CRTAM+ CD4 CTL 
can be isolated from the lung after IAV infection and lyse NP 
peptide pulsed targets, while CD4 cells from CRTAM-deficient 
mice are not cytotoxic. CRTAM interacts with its ligand CADM1, 
expressed on epithelial cells and CD8α+ DC, and there is specula-
tion that CRTAM+ CD4 CTL interact with this ligand to expand 
memory phenotype cells in  vivo (39). Whether CRTAM+ CD4 
cells can be identified in the memory pool and whether these 
cells become secondary effectors capable of cytolytic activity 
in the lung are questions that remain to be answered. Another 
cell surface receptor that may be important in identifying CD4 
CTL is the NK cell lectin receptor NKG2A. Workman et al. have 
demonstrated that a proportion of CD4+GrB+ cells in the lung 
at the effector stage express NKG2A/C/E using an antibody that 
can recognize all three isoforms (22, 40). Moreover, NKG2A gene 
expression was apparent in CD4 Th1 memory cell clones after 
IAV infection (48), and NKG2A protein expression was higher 
in secondary effectors found in the lung, compared to secondary 
effectors in the DLN (46). Interestingly, Eomes expression was 
also increased in secondary effectors suggesting Eomes may be 
more important for driving memory or secondary CD4 CTL 
responses (46, 49), but not effector CD4 CTL responses, similar 
to studies with CD8 CTL memory (41). Kinetic studies investi-
gating the expression patterns of CRTAM and NKG2A and their 
correlation with degranulation on CD4 CTL over time may yield 
valuable information regarding the transition from effector to 
memory CD4 CTL. This would be a breakthrough in the study 
of CD4 CTL as currently there exists no clear cell surface marker 
that identifies this cell type. This would also allow a more detailed 
analysis of the role of Blimp-1 and Eomes in inducing GrB and 
perforin re-expression in memory CD4 CTL.
Experiments to dissect the role of transcription factors 
important in innate cell signaling during IAV infection are on 
going and have demonstrated that interferon response factor-3 
(IRF-3) regulates GrB expression in memory CD4 and CD8 
CTL (47). Interestingly, IRF-3 does not appear to play a role in 
driving GrB expression at the effector stage after IAV infection, 
but has marked effects on antigen-specific GrB re-expression in 
the memory CD8 population. This defect was most apparent in 
the central memory phenotype and was not abrogated by innate 
cytokines, such as IL-12, IFN-β, or IL-15 (47). The level of GrB 
re-expression in memory CD4 CTL, especially in the SLO, is 
difficult to detect; however, it is thought the same defect exists 
in CD4 CTL (47). Studies are underway to fully understand the 
relationship between IRF3 and GrB expression and whether IRF3 
functions intrinsically in T cells or whether IRF3-controlled 
cytokines ultimately drive GrB expression in the memory phase.
CAN vACCiNATiON iNDUCe CD4 CTL 
FOR PROTeCTiON AGAiNST iAv?
As discussed above, immunotherapy or vaccination to elicit 
antitumor immunity results in CD4 CTL poised to eradicate 
established tumors, yet these strategies use agonistic antibodies 
to costimulatory molecules to induce high levels of activation 
and overcome tolerogenic signals (42–44). Recently, there have 
been two reports that demonstrate vaccine induced CD4 CTL 
generation via TLR4 agonist and protein (50) or complete 
Freund’s adjuvant (CFA) and viral MCMV peptide (18) immu-
nization. However, the first study demonstrated that CD4 CTL 
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generated via TLR4 agonist administration expressed granzyme 
A and killed via CD40:CD40L interactions with no role for GrB, 
perforin, or FasL-mediated cell death (50). The second study 
vaccinated mice against murine CMV using peptide and CFA 
immunization and found that CD4 CTL expressing GrB medi-
ated viral clearance upon challenge; however, the mechanism 
of cell killing by vaccine-induced CD4 CTL was not elucidated 
(18). Thus, determining the role of vaccine induced CD4 CTL 
in protection against infections is the next step in this area of 
intense research.
One of the more important studies of vaccination-induced 
CD4 CTL generation comes from work by Zhou and McElhaney 
investigating the role of IAV vaccine-induced protection in 
elderly populations (36, 37, 51). It is well documented that elderly 
subjects have diminished immune responses to vaccination with 
B cell, helper T cell, and cytotoxic T cell responses all blunted 
to some degree (52). Surprisingly, while antibody responses did 
not correlate to protection from IAV infection in elderly patients, 
the existence of vaccine-induced GrB+ cells and the level of GrB 
expression correlated to a decreased risk for influenza illness 
(36). Moreover, healthy older adults showed GrB and perforin 
expression in both the CD4 and CD8 compartments at 4 weeks 
post-vaccination, albeit, lower than in healthy young adults. 
Interestingly, at 10  weeks post-vaccination, cytotoxicity in the 
CD8 compartment decreased dramatically in older adults com-
pared to young adults, while cytotoxicity in the CD4 compart-
ment was not significantly decreased (37). These experiments 
suggest that the CD4 CTL population in adults, especially the 
elderly, can be exploited by more universal vaccines that included 
conserved, internal T cell epitopes and promote cell-mediated 
immune responses.
Presently, work by Vogel et al. is aimed at enhancing current 
IAV vaccine strategies by incorporating pattern-recognition 
receptor (PRR) agonists as adjuvants and by delivering inacti-
vated virus and adjuvant directly to the respiratory mucosa by 
intranasal immunization. To this end, single-dose intranasal 
administration of TLR-9 agonist, CpG, and heat-inactivated IAV 
was shown to promote heterosubtypic protection against lethal 
IAV challenge as measured by reduced viral titers (45). In addi-
tion, GrB expressing CD4 effectors were present in the lung after 
priming with CpG and inactivated IAV, as well as after heterosub-
typic challenge 28 days later. Interestingly, low dose x31 (H3N2) 
immunization did not induce GrB expressing CD4 effectors at 
the primary response, but did generate high numbers of CD4 
CTL in the secondary response (45), again suggesting that the 
inflammatory microenvironment in the lung may provide second 
signals for complete differentiation of CD4 CTL, as x31 infection 
does not promote as high of an inflammatory response compared 
to CpG (45) or PR8 (40). Studies are underway to definitively 
demonstrate the cytolytic capacity of vaccine-induced CD4 CTL 
in our model and to determine if other PRR agonist combinations 
can induce the CD4 CTL phenotype in mucosal tissues.
CONCLUDiNG ReMARKS
Taken together, CD4 CTL are an important component of 
the cell-mediated immune response against IAV infection. 
IAV-specific CD4 CTL are induced via IL-2 and inflammatory 
cytokine signaling in vivo and appear to require the transcrip-
tion factor Blimp-1 for development. Phenotypically, CD4 CTL 
resemble Th1 effector cells that also express GrB and perforin 
and have direct cytotoxic activity ex vivo. CD4 CTL show 
perforin-dependent protection against lethal IAV infection 
in mouse models of infection, as well as in human studies of 
experimental infection or vaccination. There remains more to 
discover regarding this potentially unique subset of CD4 T cells. 
The identification of cell surface markers, such as CRTAM and 
NKG2A, will allow a more detailed analysis of the memory and 
secondary effector potential of these cells. These insights will 
provide a greater understanding of CD4 CTL and information 
for the development of vaccine strategies that induce an extra 
armament of heterosubtypic protection against IAV strains with 
pandemic potential.
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